Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

Clinical trial NCT07257055 · RECRUITING

Trial details

NCT number: NCT07257055
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Phase 2 Study MCL BTKi Rituximab Glofitamab

Start date: 2026-04-01
Primary completion: 2028-11-24
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.